Novavax logo

Novavax

NVAX | NASDAQ
Chart Builder DCF Calculator
$8.06
-$0.46 (-5.45%)
At close: Nov 16, 2026, 4:00 PM ET
$8.07
+$0.01 (+0.14%)
After-hours: Nov 16, 2026, 7:50 PM ET
-5.45%

Rating

Updated: Nov 16, 2026
34.9
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #658/1021 (Top 64%)

Key Statistics

Market Data

Market Cap $1.33B
1D Range
7.98 8.42
52W Range
6.22 12.82

Valuation (TTM)

PE -17.52
PB -6.13
EV/EBITDA -27.90

Valuation (NTM)

Forward PE 125.25
Forward PEG 0.18
Price Target $8.00
Loading financial charts...

Profile

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The compa...

Sector Healthcare
Industry Biotechnology
Employees 749
IPO Date Dec 5, 1995
Fiscal Year January - December

Latest News

Novavax to Participate in Jefferies London Healthcare Conference

5 days ago · prnewswire.com

Novavax to Participate in Jefferies London Healthcare Conference
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

6 days ago · zacks.com

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline

11 days ago · zacks.com

NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline
Novavax Q3 Earnings Call Highlights

11 days ago · marketbeat.com

Novavax Q3 Earnings Call Highlights
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates

12 days ago · zacks.com

Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights

12 days ago · prnewswire.com

Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

19 days ago · zacks.com

Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

19 days ago · prnewswire.com

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

19 days ago · prnewswire.com

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.19
Beat +45.08%
REV
$68.3M
Beat +35.45%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Hold
Price Target
$8.00
Downside
-0.74%
Buy (3)
Hold (1)
Sell (2)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.